This morning belongs to Mirum Pharmaceuticals. The company is hosting an investor call at 8:30 a.m. ET today to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study. The announcement came Sunday evening, giving traders a single overnight window to position. By the time U.S. equities open, the data will be unblinded and the stock will have moved. That timing structure, catalyst pre-open plus a live management call, is textbook binary territory.
The Story Behind the Trade
Brelovitug is being developed for HDV, widely considered the most severe form of chronic viral hepatitis because it progresses faster toward liver-related death and liver cancer. That “no approved therapies in the U.S.” backdrop is no longer true. Gilead’s Hepcludex (bulevirtide-gmod) was approved by the FDA in 2026 under accelerated approval, the first approved treatment for chronic HDV in the U.S. But accelerated approval comes with confirmatory study obligations, and bulevirtide’s mechanism, blocking the NTCP receptor, is different from brelovitug’s approach. Brelovitug is an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg) directly.
HDV occurs in people already infected with hepatitis B. In the U.S., up to 2.4 million people are hepatitis B surface antigen-positive. Among them, 3 to 6 percent test positive for HDV antibodies, and 50 to 70 percent of those have active HDV infection based on RNA testing, translating to an estimated 70,000 to 150,000 active HDV cases. That is an orphan-sized population with serious disease severity and now, genuine commercial interest from multiple programs.
Technical and Fundamental Alignment
Mirum acquired brelovitug through its January 23, 2026 acquisition of Bluejay Therapeutics. The Phase 2b portion of AZURE-1 has already de-risked the program considerably. Mirum has previously said brelovitug showed strong antiviral activity in HDV, including prior reporting of a 100% virologic response at Week 48 in an earlier Phase 2 study, and has described the Phase 2b AZURE-1 portion as meeting its primary endpoint. Brelovitug has also been described as generally well tolerated, with injection site reactions among the most commonly reported adverse events.
On the commercial side, Mirum’s total revenue was $148.932 million in Q4 2025, up 49.8% from Q4 2024. The underlying business is not dependent on brelovitug to survive; this is option value sitting on top of a functioning rare-disease platform.
Options Perspective
This is the kind of event where defined risk is not merely a preference, it is the only rational structure. MIRM is a mid-cap rare-disease name with a 52-week range that already spans from $63 to $130. A Phase 3 read in a novel disease area, pre-open, with a live management call, can produce dislocations of 20, 30, or 40 percent in either direction before the second hour of trading.
For traders with a positive thesis on the Phase 3 data, a call debit spread provides defined risk while capturing a meaningful slice of any upside gap. Buying an at-the-money call and selling a higher-strike call on the nearest weekly expiration caps the premium at risk while still participating in a strong move to the upside. Implied volatility will be elevated going into the open and will collapse sharply once the data are digested, which means long single calls purchased after the announcement will face significant time value destruction regardless of direction. The spread structure neutralizes much of that drag. Position sizing relative to portfolio risk matters far more than strike selection this morning.
Risk Management
The thesis fails if Phase 3 data do not replicate Phase 2b efficacy, or if the composite endpoint of virologic response and ALT normalization falls short of regulatory expectations. AZURE-1 and AZURE-4 together are intended to form the basis of Mirum’s U.S. biologics license application (BLA) submission for brelovitug, meaning a miss today pushes the entire regulatory timeline out, likely by years. The stock would reflect that immediately. The competitive landscape adds another layer: Vir Biotechnology has a Phase 3 registrational program for chronic hepatitis delta (tobevibart plus elebsiran), so a Mirum stumble does not leave the category without alternatives.
The Beast Verdict
AZURE-1 is the most clearly structured binary on the calendar today. The Phase 2b data provided genuine scientific confidence, and Mirum has pointed to strong antiviral activity as a key signal. The question is whether the larger Phase 3 population holds that signal. Management’s decision to call an 8:30 a.m. investor presentation on a Sunday evening suggests they know exactly what the data show. Traders who want to express a view should do so with defined-risk structures, enter before the call begins, and size the position as if the trade goes to zero, because on a binary, it can. Monitor the composite endpoint result and management commentary on the BLA filing timeline as the two metrics that will determine where this stock closes today.
